Segment, Geographic and Other Revenue Information (Tables)

6 Months Ended

Jun. 28, 2015

Reconciliation of Revenue from Segments to Consolidated



The following table provides selected income statement information by reportable segment:
	Revenues				Earnings^(a)
(MILLIONS OF DOLLARS)	June 28, 2015		June 29, 2014		June 28, 2015			June 29, 2014
Three Months Ended
Reportable Segments:
Global Innovative Pharmaceutical (GIP)	$	3,497	$	3,547	$	2,013		$	2,009
Global Vaccines, Oncology and Consumer Healthcare (VOC)	3,133		2,579		1,678			1,157
Global Established Pharmaceutical (GEP)	5,090		6,513		3,177			4,176
Total reportable segments	11,720		12,639		6,868			7,342
Other business activities^(b)	133		63		(679		)	(713		)
Reconciling Items:
Corporate^(c)	—		—		(1,286		)	(1,287		)
Purchase accounting adjustments^(c)	—		—		(835		)	(949		)
Acquisition-related costs^(c)	—		—		(68		)	(47		)
Certain significant items^(d)	—		71		(305		)	(238		)
Other unallocated	—		—		(156		)	(105		)
	$	11,853	$	12,773	$	3,539		$	4,003

Six Months Ended
Reportable Segments:
Global Innovative Pharmaceutical business (GIP)	$	6,572	$	6,623	$	3,524		$	3,776
Global Vaccines, Oncology and Consumer Healthcare (VOC)	5,796		4,753		3,143			2,214
Global Established Pharmaceutical business (GEP)	10,104		12,503		6,433			8,225
Total reportable segments	22,473		23,879		13,100			14,215
Other business activities^(b)	244		119		(1,348		)	(1,380		)
Reconciling Items:
Corporate^(c)	—		—		(2,573		)	(2,487		)
Purchase accounting adjustments^(c)	—		—		(1,738		)	(1,957		)
Acquisition-related costs^(c)	—		—		(91		)	(77		)
Certain significant items^(d)	—		128		(532		)	(1,254		)
Other unallocated	—		—		(197		)	(210		)
	$	22,717	$	24,126	$	6,621		$	6,850


^(a)	Income from continuing operations before provision for taxes on income.

^(b)

Other business activities includes the revenues and operating results of Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales operation, which in 2015 includes the revenues and expenses related to our transitional manufacturing and supply agreements with Zoetis. Other business activities also includes the costs managed by our Worldwide Research and Development organization and our Pfizer Medical organization.


^(c)	For a description, see the “Other Costs and Business Activities” section above.


^(d)	Certain significant items are substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.

For Revenues in the second quarter and first six months of 2014, certain significant items represents revenues related to our transitional manufacturing and supply agreements with Zoetis, Inc. (Zoetis). For additional information, see Notes to Consolidated Financial Statements––Note 2D. Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures, and Equity-Method Investments: Divestitures included in our 2014 Financial Report, which was filed as Exhibit 13 to our 2014 Annual Report on Form 10-K.

For Earnings in the second quarter of 2015, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $91 million, (ii) charges for certain legal matters of $92 million, (iii) charges for business and legal entity alignment of $63 million and (iv) other charges of $58 million. For additional information, see Note 3 and Note 4.

For Earnings in the second quarter of 2014, certain significant items includes: (i) charges for certain legal matters of $4 million, (ii) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $212 million, (iii) charges for business and legal entity alignment of $39 million and (iv) other income of $17 million. For additional information, see Note 3 and Note 4.

Reconciliation of Operating Profit (Loss) from Segments to Consolidated



The following table provides selected income statement information by reportable segment:
	Revenues				Earnings^(a)
(MILLIONS OF DOLLARS)	June 28, 2015		June 29, 2014		June 28, 2015			June 29, 2014
Three Months Ended
Reportable Segments:
Global Innovative Pharmaceutical (GIP)	$	3,497	$	3,547	$	2,013		$	2,009
Global Vaccines, Oncology and Consumer Healthcare (VOC)	3,133		2,579		1,678			1,157
Global Established Pharmaceutical (GEP)	5,090		6,513		3,177			4,176
Total reportable segments	11,720		12,639		6,868			7,342
Other business activities^(b)	133		63		(679		)	(713		)
Reconciling Items:
Corporate^(c)	—		—		(1,286		)	(1,287		)
Purchase accounting adjustments^(c)	—		—		(835		)	(949		)
Acquisition-related costs^(c)	—		—		(68		)	(47		)
Certain significant items^(d)	—		71		(305		)	(238		)
Other unallocated	—		—		(156		)	(105		)
	$	11,853	$	12,773	$	3,539		$	4,003

Six Months Ended
Reportable Segments:
Global Innovative Pharmaceutical business (GIP)	$	6,572	$	6,623	$	3,524		$	3,776
Global Vaccines, Oncology and Consumer Healthcare (VOC)	5,796		4,753		3,143			2,214
Global Established Pharmaceutical business (GEP)	10,104		12,503		6,433			8,225
Total reportable segments	22,473		23,879		13,100			14,215
Other business activities^(b)	244		119		(1,348		)	(1,380		)
Reconciling Items:
Corporate^(c)	—		—		(2,573		)	(2,487		)
Purchase accounting adjustments^(c)	—		—		(1,738		)	(1,957		)
Acquisition-related costs^(c)	—		—		(91		)	(77		)
Certain significant items^(d)	—		128		(532		)	(1,254		)
Other unallocated	—		—		(197		)	(210		)
	$	22,717	$	24,126	$	6,621		$	6,850


^(a)	Income from continuing operations before provision for taxes on income.

^(b)


^(c)	For a description, see the “Other Costs and Business Activities” section above.


^(d)	Certain significant items are substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.

Schedule of Revenues by Geographic Region



The following table provides revenues by geographic area:
	Three Months Ended						Six Months Ended
(MILLIONS OF DOLLARS)	June 28, 2015		June 29, 2014		% Change		June 28, 2015		June 29, 2014		% Change
United States	$	4,994	$	4,906	2		$	9,428	$	9,181	3
Developed Europe^(a)	2,380		3,008		(21	)	4,691		5,803		(19	)
Developed Rest of World^(b)	1,558		1,861		(16	)	3,050		3,589		(15	)
Emerging Markets^(c)	2,921		2,998		(3	)	5,548		5,553		—
Revenues	$	11,853	$	12,773	(7	)	$	22,717	$	24,126	(6	)


^(a)	Developed Europe region includes the following markets: Western Europe, Finland and the Scandinavian countries. Revenues denominated in euros were $1.8 billion and $2.3 billion in the second quarter of 2015 and 2014, respectively, and $3.6 billion and $4.5 billion in the first six months of 2015 and 2014, respectively.


^(b)	Developed Rest of World region includes the following markets: Australia, Canada, Japan, New Zealand and South Korea.


^(c)	Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, the Middle East, Eastern Europe, Africa, Turkey and Central Europe.

Schedule of Significant Product Revenues



The following table provides detailed revenue information:
		Three Months Ended				Six Months Ended
(MILLIONS OF DOLLARS)	Business^(a)	June 28, 2015		June 29, 2014		June 28, 2015		June 29, 2014
Biopharmaceutical revenues:
Prevnar family^(b)	V	$	1,503	$	1,097	$	2,808	$	2,024
Lyrica^(c)	GEP/GIP	1,219		1,315		2,406		2,465
Enbrel (Outside the U.S. and Canada)	GIP	822		977		1,581		1,891
Lipitor	GEP	509		543		950		1,000
Viagra^(d)	GEP/GIP	448		427		843		801
Sutent	O	294		310		536		578
Zyvox	GEP	259		348		530		669
Norvasc	GEP	251		282		503		560
Premarin family	GEP	259		274		491		522
Celebrex	GEP	224		762		428		1,386
BeneFIX	GIP	193		227		366		428
Vfend	GEP	162		221		345		398
Pristiq	GEP	177		198		338		370
Chantix/Champix	GIP	173		170		332		317
Genotropin	GIP	167		194		306		360
Refacto AF/Xyntha	GIP	142		171		262		316
Xalkori	O	119		108		230		196
Xeljanz	GIP	128		68		224		120
Medrol	GEP	113		115		215		221
Inlyta	O	111		101		206		189
Xalatan/Xalacom	GEP	99		128		201		247
Zoloft	GEP	93		104		179		205
Sulperazon	GEP	80		92		179		180
Ibrance	O	140		—		178		—
Relpax	GEP	82		98		162		185
Fragmin	GEP	88		95		162		176
EpiPen	GEP	85		89		161		152
Zithromax/Zmax	GEP	68		76		154		168
Tygacil	GEP	77		82		150		156
Effexor	GEP	74		96		147		178
Toviaz	GIP	71		79		134		142
Revatio	GEP	65		68		128		144
BMP2	GIP	75		51		113		90
Xanax/Xanax XR	GEP	54		68		109		127
Cardura	GEP	55		68		106		134
Rapamune	GIP	53		87		106		175
Unasyn	GEP	50		54		105		100
Somavert	GIP	55		59		104		109
Neurontin	GEP	48		58		103		107
Depo-Provera	GEP	51		40		88		93
FSME-IMMUN/TicoVac	V	56		—		65		—
Alliance revenues^(e)	GEP/GIP	311		235		533		448
All other GIP	GIP	87		131		178		237
All other GEP	GEP	1,623		1,910		3,256		3,749
All other V/O	V/O	70		51		124		93
Total biopharmaceutical revenues	GEP/GIP/V/O	10,880		11,727		20,824		22,206
Other revenues:
Consumer Healthcare	C	840		912		1,648		1,673
Other^(f)		133		134		244		247
Revenues		$	11,853	$	12,773	$	22,717	$	24,126


^(a)	Indicates the business to which the revenues relate. GIP = the Global Innovative Pharmaceutical segment; V = the Global Vaccines

business; O = the Global Oncology business; C = the global Consumer Healthcare business; and GEP = the Global Established Pharmaceutical segment.


^(b)	In the second quarter and the first six months of 2015, all revenues were composed of Prevnar 13/Prevenar 13. In the second quarter and the first six months of 2014, revenues were composed of the Prevnar family of products, which included Prevnar 13/Prevenar 13 and, to a much lesser extent, Prevenar (7-valent).


^(c)	Lyrica revenues from all of Europe, Russia, Turkey, Israel and Central Asia countries are included in GEP. All other Lyrica revenues are included in GIP.


^(d)	Viagra revenues from the U.S. and Canada are included in GIP. All other Viagra revenues are included in GEP.


^(e)	Includes Eliquis (GIP), Rebif (GIP), Spiriva (GEP) and Aricept (GEP).


^(f)	Other includes revenues generated from Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales organization, and revenues related to our transitional manufacturing and supply agreements with Zoetis.